Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
55
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study

Yusuke KitagawaDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Hiroki OsumiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Eiji ShinozakiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanCorrespondence[email protected]
,
Yumiko OtaDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Izuma NakayamaDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Takeshi SuzukiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Takeru WakatsukiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Takashi IchimuraDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Mariko OguraDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Akira OokiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Daisuke TakahariDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Mitsukuni SuenagaDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
,
Keisho ChinDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
&
Kensei YamaguchiDepartment of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
 show all
Pages 5757-5764 | Published online: 25 Jun 2019

References

  • Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11–16. doi:10.1016/j.anndiagpath.2017.04.00528807335
  • Yamaguchi T, Machida N, Morizane C, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014;105(9):1176–1181. doi:doi:10.1111/cas.1247324975505
  • Brenner B, Tang LH, Shia J, Klimstra DS, Kelsen DP. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol. 2007;34(1):43–50. doi:doi:10.1053/j.seminoncol.2006.10.02217270665
  • Asayama M, Fuse N, Yoshino T, et al. Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases. Cancer Chemother Pharmacol. 2011;68(5):1325–1330. doi:10.1007/s00280-011-1619-721461890
  • Chin K, Baba S, Hosaka H, et al. Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience. Jpn J Clin Oncol. 2008;38(6):426–431. doi:10.1093/jjco/hyn04118519543
  • Okita NT, Kato K, Takahari D, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011;14(2):161–165. doi:10.1007/s10120-011-0025-521327441
  • Morizane C, Machida N, Honma Y, et al. Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: a Japan Clinical Oncology Group study (JCOG1213). J Clin Oncol. 2015;33:TPS4143–TPS4143. doi:doi:10.1200/jco.2015.33.15_suppl.tps4143
  • von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–4019. doi:doi:10.1200/jco.2013.54.539225385727
  • Ando T, Hosokawa A, Yoshita H, et al. Amrubicin monotherapy for patients with platinum-refractory gastroenteropancreatic neuroendocrine carcinoma. Gastroenterol Res Pract. 2015;2015:1–5. doi:doi:10.1155/2015/425876
  • Nio K, Arita S, Isobe T, et al. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemother Pharmacol. 2015;75(4):829–835. doi:10.1007/s00280-015-2706-y25702050
  • Araki T, Takashima A, Hamaguchi T, et al. Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anticancer Drugs. 2016;27(8):794–799. doi:10.1097/cad.000000000000039327341105
  • Yoshioka H, Katakami N, Okamoto H, et al. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2016;28(2):285–291. doi:10.1093/annonc/mdw621
  • Haider K, Shahid RK, Finch D, et al. Extrapulmonary small cell cancer. Cancer. 2006;107(9):2262–2269. doi:10.1002/cncr.2223516998932
  • Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma. Cancer. 2007;110(5):1068–1076. doi:10.1002/cncr.2288717614337
  • Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2017;124(4):807–815. doi:10.1002/cncr.3112429211313
  • Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications. Cancer Treat Rev. 2016;50:61–67. doi:10.1016/j.ctrv.2016.08.00627636009
  • Mishima S, Kawazoe A, Matsumoto H, et al. Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. ESMO Open. 2018;3:e000443. doi:10.1136/esmoopen-2018-00044330425849
  • Hata A, Katakami N, Fujita S, et al. Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer. Lung Cancer. 2011;72(2):224–228. doi:10.1016/j.lungcan.2010.08.00920828862

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.